“Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S17. doi:10.25251/skin.3.supp.17.